Xeljanz (tofacitinib) works by blocking enzymes called Janus kinases (JAKs) inside your immune cells, which interrupts the chemical signaling that drives inflammation in autoimmune diseases. Unlike older biologics that target a single protein outside the cell, Xeljanz works inside the cell to dial down multiple inflammatory pathways at once. It’s FDA-approved for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis in adults who haven’t responded to other treatments.
The JAK-STAT Pathway, Explained
Your immune system communicates through small signaling proteins called cytokines. When a cytokine docks on the surface of an immune cell, it activates JAK enzymes just inside the cell membrane. Those JAK enzymes then switch on proteins called STATs, which travel to the cell’s nucleus and tell it to produce more inflammatory compounds, multiply, or attack tissue. In autoimmune diseases, this process runs on overdrive, producing chronic inflammation that damages joints, the gut lining, or the spine.
Xeljanz blocks JAK1 and JAK3 most strongly, with some effect on JAK2. Because different cytokines rely on different combinations of JAKs, this single drug dampens signaling from a wide range of inflammatory messengers: IL-2, IL-4, IL-6, IL-15, IL-21, interferons, and others. In clinical studies, the degree of suppression ranged from 10% to 73% depending on the cytokine and the type of immune cell. The strongest inhibition, at 50% or greater, was seen for interferons and a family of cytokines (IL-2, IL-4, IL-15, IL-21) that drive T cell activation, a central player in autoimmune damage.
How This Differs From Biologics
Most biologic drugs for autoimmune disease are large proteins delivered by injection or infusion. They work outside the cell by physically binding to one specific cytokine or receptor. TNF blockers, for example, neutralize a single inflammatory protein called tumor necrosis factor. If your disease is driven by other pathways beyond TNF, a TNF blocker may not be enough.
Xeljanz is a small molecule taken as a pill. Instead of blocking one cytokine at a time, it enters immune cells and interrupts the internal machinery that multiple cytokines depend on. This broader reach is why it can help people whose disease didn’t respond to TNF blockers. It’s also why Xeljanz carries a different risk profile, since suppressing more pathways means a wider effect on your immune system overall.
What It Treats
Xeljanz is approved specifically for people who tried at least one TNF blocker and either didn’t improve or couldn’t tolerate it. In adults, approved conditions include moderately to severely active rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderately to severely active ulcerative colitis. For children ages 2 and older, it’s approved for active psoriatic arthritis and a form of juvenile arthritis called polyarticular course juvenile idiopathic arthritis.
How Quickly It Works
Xeljanz starts working faster than many people expect. In rheumatoid arthritis trials, patients showed measurably better joint symptoms within two weeks compared to placebo. The same two-week timeline held for psoriatic arthritis. In ulcerative colitis, decreases in rectal bleeding and stool frequency were also visible by week two. That said, two weeks marks the beginning of improvement, not the full effect. Most patients continue to see gains over the first three to six months of treatment.
How You Take It
Xeljanz comes in two tablet forms. The immediate-release version is typically a 5 mg tablet taken twice daily. An extended-release version (Xeljanz XR) delivers 11 mg once daily, which is more convenient for many people. There’s also an oral solution (1 mg per milliliter) for patients who have trouble swallowing pills or need precise dosing, including children. The drug is processed primarily by a liver enzyme called CYP3A4, with a minor role from CYP2C19. Its half-life is roughly three hours, which is why the immediate-release form needs to be taken twice a day. Certain other medications that affect these same liver enzymes can change how much Xeljanz stays in your system, so your doctor will review drug interactions before prescribing.
Safety Risks to Know About
Xeljanz carries the FDA’s most serious warning label, a boxed warning, based on results from a large safety trial. That trial enrolled over 4,300 rheumatoid arthritis patients aged 50 and older who had at least one cardiovascular risk factor, comparing Xeljanz at two doses against a TNF blocker. Patients on Xeljanz had higher rates of serious heart-related events (heart attack and stroke), cancer, blood clots, and death compared to those on the TNF blocker.
The numbers put this in perspective. The risk of major cardiovascular events was about 33% higher with Xeljanz than with TNF blockers, though the confidence interval was wide enough that the increase could have been smaller or somewhat larger. For cancers other than common skin cancers, the risk was about 48% higher, and that finding was statistically significant. Lymphoma rates were elevated. Lung cancer rates were particularly elevated among current or past smokers, who also faced a higher risk of cancer overall.
These risks were dose-dependent for heart events, blood clots, and death, meaning higher doses carried greater risk. Cancer risk was elevated at both doses without a clear dose relationship. This is a key reason Xeljanz is reserved for patients who have already tried and failed a TNF blocker rather than being used as a first-line treatment.
Common Side Effects
Beyond the serious risks covered by the boxed warning, the most frequently reported side effects are upper respiratory infections, headache, diarrhea, and nasal congestion. Because Xeljanz broadly suppresses immune signaling, infections are a real concern. Shingles occurs more often in people taking Xeljanz than in those on many other immune-suppressing drugs, so vaccination before starting treatment is typically recommended. Routine blood work monitors for drops in white blood cell counts, increases in cholesterol, and changes in liver enzymes, all known effects of JAK inhibition that your care team will track over time.